Mechanistic Modeling and Realistic In Vitro Models to Facilitate Development of Generic Nasal Drug Products

SBIA 2022 – Advancing Generic Drug Development: Translating Science to Approval

Day 2, Session 6: Nasally Administered Drug Products

Ross Walenga, Ph.D.

Chemical Engineer
Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs
CDER | U.S. FDA
September 21, 2022

Learning Objectives

- Describe the utility computational fluid dynamics (CFD) and physiologically based pharmacokinetic (PBPK) modeling for nasal drug product development.

- Understand how CFD and PBPK modeling are used to identify potential relationships between in vitro metrics and drug delivery to the site of action for nasal drug products.

- Identify the value of CFD and PBPK modeling for development of nasal drug products with targeted nose-to-brain drug delivery.

Research for Mechanistic Modeling of Nasal Drug Products and In Vitro Nasal Models

- Funded supported via Generic Drug User Fee Amendments (GDUFA)

- Six external grants and contracts (three ongoing)

  - Grant 1U01FD005201 (Applied Research Associates [ARA], 2014-2018)

  - Grant 1U01FD006537 (North Carolina State University [NCSU], 2018-2021)

  - Contract HHSF223201810144C (Virginia Commonwealth University [VCU], 2018-2021)

  - Contract 75F40119C10079 (ARA, 2019-present)

  - Contract 75F40120C00172 (VCU, 2020-present)

  - Grant 1U01FD007657 (University of Manchester, 2022-present)

Value of Mechanistic and In Vitro Models

- Product Development

  – Influence of device and formulation differences on regional deposition and absorption

  – Prediction of olfactory region absorption for nose-to-brain (N2B) delivery

- Bioequivalence (BE)

  – May be useful for alternative BE approaches for nasal drug products

# Computational Fluid Dynamics (CFD) Modeling of NDPs

- Predict influence of device and formulation parameters on drug delivery to the site of action

  - Particle size distribution, spray angle, spray velocity

  - Regional deposition

    - Intersubject variability

  - Pharmacokinetic (PK) profile

    - Combined with physiologically-based pharmacokinetic (PBPK) modeling

Fiber deposition in nasal cavity, where a is the fiber radius in μm, β is the fiber aspect ratio, IP is the impaction parameter, and DF is the deposition fraction. (Fig. 13 from Dastan et al.[1])

Nasal In Vitro Models


Cut-open view of the left nasal passage

Cut-out olfactory region (OL)

OL1   OL2

Nasal in vitro model that allows for measurement of olfactory region deposition. (Adapted from Fig. 1c of Xi et al.[2])

- Drug product is actuated into nasal model

- Deposited drug is measured from removable sections using high performance liquid chromatography (HPLC)

- Capable of evaluating intersubject variability

PBPK Modeling of NDPs

Nasal PBPK model structure as shown in Fig. 2 of Andersen et al.[3]

- Compartmental model

- Regional deposition inputs (in vivo, in vitro, or in silico)

- Prediction of local and systemic PK

  – Dissolution in mucus layer

  – Absorption through nasal tissue

  – Metabolism in nasal tissue

  – Integration with systemic model

- Validated with in vivo systemic or tissue PK data

Regional Deposition Measurements

Experimental setup for measuring deposition following actuation of fluticasone propionate nasal spray. (Fig. 2 of Manniello et al.[4])

- VCU

  - PI: Laleh Golshahi

  - Contract #HHSF223201810144C (adult models)

  - Contract #75F4012000172 (pediatric models)

  - Develop two sets of models for adult and pediatric subjects (three models for each)

  - Intersubject variability for nasally inhaled corticosteroids

- Relationships of in vitro metrics of spray properties with regional deposition

Poster Region Deposition Measurements

- Posterior regional deposition measurements showed high variability
  - Range of 12-99% for fluticasone propionate nasal spray
  - Range of 29-92% for fluticasone furoate nasal spray

- In several cases there was a significant difference according to drug product

Posterior regional deposition in right side of 40 adult nasal airways (n = 5 for each model) of fluticasone propionate nasal spray (Flonase®) and hand-actuated fluticasone furoate nasal spray (Flonase Sensimist®). Significant differences between drug products are shown by "*." (Fig. 4 of Alfaifi et al.[5])

Nasal Model Selection

- Three adult nasal models have been selected to capture intersubject variability according to following criteria:

  - Low and high deposition models must differ by two standard deviations from the mean value of posterior deposition for all 40 models. The medium model should be not significantly different than the mean

  - No significant difference between drug products

  - Significant differences between low and medium models and between high and medium models

Posterior regional deposition in three selected models (n = 5 for each model) of fluticasone propionate nasal spray and hand-actuated fluticasone furoate nasal spray. (Fig. 7 of Alfaifi et al.[5])

Further Sectioning of Nasal Models

Computational rendering of high posterior deposition model sectioned into anterior, front, inferior turbinate, middle turbinate, superior turbinate, and nasopharynx regions. (Fig. 4 of Golshahi et al.[6])

Mean percentage of recovered regional deposition ± standard deviation in three selected models (n = 5 for each model) of fluticasone propionate nasal spray. (Based on Table 2 of Golshahi et al.[6])

Posterior Section	Posterior Deposition		
	High	Medium	Low
Anterior	23.2 ± 4.2	52.5 ± 0.8	64.1 ± 0.9
Front	37.9 ± 4.5	22.4 ± 1.1	15.8 ± 1.2
Inferior	32.4 ± 6.1	20.0 ± 2.1	17.2 ± 1.0
Middle	3.0 ± 2.4	3.0 ± 1.4	1.2 ± 0.5
Superior	1.6 ± 1.0	2.3 ± 1.1	0.0 ± 0.0
Nasopharynx	1.8 ± 0.2	0.0 ± 0.0	0.7 ± 0.1

Comparison of Different Products

- Relationships of in vitro metrics to regional deposition may be tested with three in vitro nasal models

- Three in vitro tests

  – Droplet size distribution

  – Plume geometry

  – Spray pattern

- Two brand-name fluticasone propionate nasal spray drug products (Flonase Allergy Relief® and Flonase) and three generic versions of Flonase (Akorn, Apotex, and West-ward)

Median droplet diameter (Dv50), plume angle, plume area at 6 cm, and ratio of front to inferior turbinate deposition across high, medium, and low models, for two brand-name fluticasone propionate nasal drug products (Flonase Allergy Relief [with 144 sprays] and Flonase [with 120 sprays]) and three generic versions of Flonase. * - significantly different. (Fig. 6 of Golshahi et al.[6])

CFD Model Validation

Deposition predictions using two CFD methods with fluticasone furoate nasal spray and fluticasone propionate nasal spray as compared with in vitro data (n = 5). (Based on Table 6 of Kolanjiyil et al.[7])

|	Fluticasone Furoate		Fluticasone Propionate	
	Anterior (%)	Posterior (%)	Anterior (%)	Posterior (%)
CFD quasi two-way coupling	93.4	6.6	89.5	10.5
CFD one-way coupling	92.6	7.4	94.0	6.0
In vitro	94.1 ± 1.9	5.9 ± 1.9	85.8 ± 5.4	14.2 ± 5.4
Relative error (quasi two-way coupling) (%)	0.7	11.9	4.3	26.1
Relative error (one-way coupling) (%)	1.6	25.4	9.6	57.7

- Model credibility should be established before using model for intended purpose

- One nasal model from Manniello et al.[4] was used to develop CFD model

- Two methods used to couple fluid and particle motion

- Results compared to in vitro data

- Improvement of predictions may be possible by considering spray-wall interaction and post-deposition liquid motion[8]

Influence of Spray Cone Angle

CFD simulation results with Medium nasal model and fluticasone furoate nasal spray, shown as (A) variation in spray cone angle input parameter, (B) anterior and posterior deposition percentage predictions, and (C) relative difference (RD) in posterior deposition fraction (PD) as varied by relative difference in spray cone angle (baseline of 35°). (Fig. 1 of Kolanjiyil et al.[9])

Hybrid CFD-PBPK for Nasally Inhaled Corticosteroids

CFD predictions for deposition locations of fluticasone propionate droplets, from Kimbell et al.[10]

PK predictions of fluticasone propionate nasal spray, from Schroeter et al.[11]

- Applied Research Associates, Inc.
  - Grant #1U01FD005201: 2014-2018
  - Contract #75F40119C10079: 2019-present
  - Principal Investigator (PI): Jeffry Schroeter
- Fully 3D CFD model predicts deposition
- PBPK model for nasal absorption
- CFD results serve as inputs to the PBPK model
  - Models are run independently
  - Constant mucociliary clearance (MCC) velocity
- Investigation of device and usage parameters

In Vitro Metrics – Input Parameters

- CFD modeling was used to examine impact of various in vitro parameters on regional deposition predictions

- Input parameters were varied by ± 10% and ± 20% to understand parameter sensitivity

[a] Next Breath report, Kimbell R01[12]

[b] Schroeter et al.[13]

[c] Xi et al.[14]

[d] Hosseini et al.[15]

* Estimated valued based on Shrestha et al.[16]

CFD input parameters for several brand name drug products (Based on table produced by ARA for contract 75F40119C10079)

Spray	Spray Cone Angle (degrees)	Dv50 (µm)	Span
Fluticasone Propionate	63.3 ± 4.2 [a]	46.4 ± 2.1 [b]	2.04 ± 0.32 [b]
Triamcinolone Acetonide	55.9 ± 0.9 [a]	43.8 ± 2.8 [a]	1.99 ± 0.27 [a]
Mometasone Furoate	20.0 ± 0.5 [c]	41.4 ± 1.1 [b]	1.91 ± 0.25 [b]
Budesonide	59.4 ± 18.3 *	29.4 ± 1.7 [b]	2.42 ± 1.23 [b]
Fluticasone Furoate	35 ± 2.1 [d]	57.1 ± 1.3 [d]	1.39 ± 0.01 [d]

Regional Definitions for Nasal Models

Regional definitions for healthy subject model
MCW002 (Figure produced by ARA for contract
75F40119C10079)

Sensitivity of Regional Deposition to In Vitro Metric Variation

Regional deposition results for fluticasone propionate nasal spray (Flonase), triamcinolone acetonide nasal spray (Nasacort), mometasone furoate nasal spray (Nasonex), budesonide nasal spray (Rhinocort), and fluticasone furoate nasal spray (Flonase Sensimist) (Based on figures produced by ARA for contract 75F40119C10079)

PBPK Model Validation for Fluticasone Propionate Nasal Spray

PBPK model validation following administration of fluticasone propionate nasal spray with a dose of 200 µg, as given in publicly available review for abbreviated new drug application (ANDA) 77570 with test and reference products,[17] and a dose of 800 µg given four times as given in Daley-Yates et al.[18] (Based on figures produced by ARA for contract 75F40119C10079)

Impact of Spray Cone Angle on PK

Systemic and tissue PK predictions for fluticasone propionate (FP) nasal spray based on differences in spray cone angle (Based on figures produced by ARA for contract 75F40119C10079)

Nasal Modeling to Predict Nose-to-Brain Drug Delivery

Nasal MCC model features, including a) 6 mm/min mucus velocity vectors in mucus layer and b) regional definitions including olfactory (red), nasal vestibule (blue), and nasal cavity (orange) regions. (Fig. 1 of Chari et al.[19])

- North Carolina State University
  - PI: Clement Kleinstreuer
  - Grant #1U01FD006537: 2018-2021
  - 3D CFD model is used to predict regional deposition of NDPs
  - Nasal MCC model predicts transit, dissolution, and absorption simultaneously
  - Can be used for predicting nose-to-brain drug delivery

- Other models (e.g., ARA and VCU) may be used for nose-to-brain drug delivery provided effect of mucociliary clearance is not expected to be pronounced

- PBPK model for nose-to-brain drug delivery is focus of new award to University of Manchester (Grant #1U01FD007657, PI: Kayode Ogungbenro, 2022-present)

Challenge Question #1

Which of the following statements is **NOT** true?

A. Nasal in vitro models may be sectioned to allow for measurement of regional deposition using high performance liquid chromatography (HPLC).

B. Computational fluid dynamics (CFD) modeling is a physics-based method that allows for prediction of fluid and particle transport only in simplified geometries.

C. Physiologically based pharmacokinetic (PBPK) modeling is a compartmental method that allows for prediction of pharmacokinetics (PK) following drug administration.

Challenge Question #2

Nose-to-brain drug delivery is achieved by targeting which nasal region?

A. Nasal vestibule

B. Olfactory

C. Nasopharynx

D. Inferior turbinate

Conclusions

1. GDUFA supports several external research grants and contracts for enhancing generic nasal drug product development.

2. Mechanistic CFD and PBPK models and realistic in vitro nasal models are being developed to investigate relationships between in vitro test metrics and regional drug delivery and to better understand regional delivery of drugs that target nose-to-brain drug delivery.

3. Mechanistic modeling and realistic in vitro nasal models may facilitate development and potentially approval of nasal drug products.

Acknowledgements

- FDA/CDER/OGD/ORS
  - Khondoker Alam
  - Andrew Babiskin
  - Betsy Ballard
  - Elizabeth Bielski
  - Susan Boc
  - Steven Chopski
  - Sneha Dhapare
  - Liangfeng Han
  - Bryan Newman
  - Mingliang Tan
  - Eleftheria Tsakalozou
  - Miyoung Yoon

- FDA/CDER/OGD/ORS
  - Lanyan (Lucy) Fang
  - Myong-Jin Kim
  - Darby Kozak
  - Liang Zhao
  - Markham Luke
  - Lei Zhang
  - Robert Lionberger
- FDA/CDER/OGD/OSCE
  - Kimberly Witzmann
  - Sharon Ahluwalia
  - Denise Conti
- FDA/CDER/OPQ/OLDP
  - Srinivas Behara
- FDA/CDER/OPQ/ONDP
  - Renishkumar Delvadia
- FDA/CDER/OPQ/OTR
  - Geng Tian
  - Maziar Kakhi
- FDA/CDER/OTS/OCP
  - Bhawana Saluja

- VCU
  - P. Worth Longest
  - Laleh Golshahi
  - Michael Hindle
- Applied Research Associates, Inc.
  - Jeffrey Schroeter
- University of North Carolina
  - Julie Kimbell
  - William (Bill) Bennett
- North Carolina State University
  - Clement Kleinstreuer
  - Sriram Chari

References

1. Dastan A, Abouali O, Ahmadi G. CFD simulation of total and regional fiber deposition in human nasal cavities. J Aerosol Sci. 2014;69:132-49.

2. Xi J, Wang Z, Nevorski D, White T, Zhou Y. Nasal and olfactory deposition with normal and bidirectional intranasal delivery techniques: in vitro tests and numerical simulations. Journal of aerosol medicine and pulmonary drug delivery. 2017;30(2):118-31.

3. Andersen ME, Green T, Frederick CB, Bogdanffy MS. Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate. Regulatory Toxicology and Pharmacology. 2002;36(3):234-45.

4. Manniello MD, Hosseini S, Alfaifi A, Esmaeili AR, Kolanjiyil AV, Walenga R, Babiskin A, Sandell D, Mohammadi R, Schuman T, Hindle M. In vitro evaluation of regional nasal drug delivery using multiple anatomical nasal replicas of adult human subjects and two nasal sprays. International Journal of Pharmaceutics. 2021;593:120103.

5. Alfaifi A, Hosseini S, Esmaeili AR, Walenga R, Babiskin A, Schuman T, Longest W, Hindle M, Golshahi L. Anatomically Realistic Nasal Replicas Capturing the Range of Nasal Spray Drug Delivery in Adults. International Journal of Pharmaceutics. 2022:121858.

6. Golshahi L, Alfaifi A, Hosseini S, Esmaeili AR, Hindle M, Longest W, Schuman TA. Leveraging in vitro bioequivalence tests for locally-acting suspension nasal sprays with three anatomically-correct replicas of human nasal airways representing intersubject variability. Respiratory Drug Delivery (RDD). 2022;1: 37-46.

References (cont'd)

7. Kolanjiyil AV, Hosseini S, Alfaifi A, Farkas D, Walenga R, Babiskin A, Hindle M, Golshahi L, Longest PW. Validating CFD predictions of nasal spray deposition: Inclusion of cloud motion effects for two spray pump designs. Aerosol Science and Technology. 2022;56(4):305-22.

8. Kolanjiyil AV, Alfaifi A, Aladwani G, Golshahi L, Longest W. Importance of Spray–Wall Interaction and Post-Deposition Liquid Motion in the Transport and Delivery of Pharmaceutical Nasal Sprays. Pharmaceutics. 2022;14(5):956.

9. Kolanjiyil AV, Hosseini S, Alfaifi A, Hindle M, Golshahi L and Longest PW: How spray metric variability impacts the initial deposition of nasal sprays. Respiratory Drug Delivery 2021,1:349-354.

10. Kimbell J, Schroeter J, Tian G, Walenga R, Babiskin A, Delvadia R. Estimating size-specific numbers of active pharmaceutical ingredient particles in the regional deposition of a nasal spray. J Aerosol Med Pulm Drug Deliv. 2017;30(3):18-19.

11. Schroeter J, Kimbell J, Walenga R, Babiskin A, Delvadia R. A CFD-PBPK model to simulate nasal absorption and systemic bioavailability of intranasal fluticasone propionate. J Aerosol Med Pulm Drug Deliv. 2017;30(3):13-14.

12. Next Breath Report, Kimbell R01

13. Schroeter JD, Kimbell JS, Saluja B, Delvadia RR, Vallorz III EL, Sheth P. The impact of actuation force on droplet size distribution and spray duration of three commercially available nasal sprays. Respiratory Drug Delivery (RDD) 2016. 2016;1:261-264.

14. Xi J, Yuan JE, Zhang Y, Nevorski D, Wang Z, Zhou Y. Visualization and quantification of nasal and olfactory deposition in a sectional adult nasal airway cast. Pharmaceutical research. 2016;33(6):1527-41.

References (cont'd)

15. Hosseini S, Wei X, Wilkins Jr JV, Fergusson CP, Mohammadi R, Vorona G, Golshahi L. In vitro measurement of regional nasal drug delivery with Flonase,® Flonase® Sensimist,™ and MAD Nasal™ in anatomically correct nasal airway replicas of pediatric and adult human subjects. Journal of aerosol medicine and pulmonary drug delivery. 2019;32(6):374-85.

16. Shrestha K, Van Strien J, Singh N, Inthavong K. Primary break-up and atomization characteristics of a nasal spray. Plos one. 2020;15(8):e0236063.

17. Bioequivalence review for ANDA 77570. Accessed on 6/24/2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/anda/2008/077570Orig1s000BioeqR.pdf.

18. Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. British journal of clinical pharmacology. 2001;51(1):103-5.

19. Chari S, Sridhar K, Walenga R, Kleinstreuer C. Computational analysis of a 3D mucociliary clearance model predicting nasal drug uptake. Journal of Aerosol Science. 2021;155:105757.